Intellia Historical Cash Flow
| NTLA Stock | USD 8.07 0.33 3.93% |
Analysis of Intellia Therapeutics cash flow over time is an excellent tool to project Intellia Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Total Cashflows From Investing Activities of 151.5 M or Other Cashflows From Financing Activities of 8.4 M as it is a great indicator of Intellia Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Intellia Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Intellia Therapeutics is a good buy for the upcoming year.
Intellia |
About Intellia Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Intellia balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Intellia's non-liquid assets can be easily converted into cash.
Intellia Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Capital Expenditures
Capital Expenditures are funds used by Intellia Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Intellia Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Intellia Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Intellia Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.At present, Intellia Therapeutics' Stock Based Compensation is projected to increase significantly based on the last few years of reporting. The current year's Change In Working Capital is expected to grow to about 12.5 M, whereas Sale Purchase Of Stock is forecasted to decline to about 375.6 M.
Intellia Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Intellia Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Intellia Therapeutics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Sale Purchase Of Stock | 76.4M | 371.8M | 1.9B | 583.0M | 670.4M | 375.6M | |
| Change In Cash | 107.4M | (39.1M) | 410.0M | (295.1M) | (265.6M) | (252.3M) | |
| Stock Based Compensation | 19.9M | 47.0M | 91.4M | 134.1M | 154.2M | 161.9M | |
| Free Cash Flow | (53.5M) | (237.8M) | (391.7M) | (408.1M) | (367.3M) | (348.9M) | |
| Change In Working Capital | 57.5M | (22.9M) | (53.9M) | (52.5M) | 11.9M | 12.5M | |
| Total Cashflows From Investing Activities | 25.2M | (214.5M) | (550.8M) | 160.3M | 144.3M | 151.5M | |
| Other Cashflows From Financing Activities | 13.1M | 43.1M | 17.2M | 10.5M | 8.8M | 8.4M | |
| Depreciation | 6.3M | 6.9M | 7.6M | 9.0M | (16.9M) | (16.1M) | |
| Other Non Cash Items | 573K | 2.9M | 95.8M | (3.5M) | (30.0M) | (28.5M) | |
| Capital Expenditures | 3.6M | 12.8M | 58.4M | 14.0M | 16.1M | 13.5M | |
| Total Cash From Operating Activities | (49.9M) | (225.0M) | (333.3M) | (394.1M) | (354.7M) | (336.9M) | |
| Change To Account Receivables | 2.5M | 99K | (1.7M) | (32.7M) | 27.9M | 29.3M | |
| Change To Operating Activities | 1.7M | 4.9M | 7.8M | 15.9M | 18.3M | 19.2M | |
| Net Income | (134.2M) | (267.9M) | (474.2M) | (481.2M) | (433.1M) | (411.4M) | |
| Total Cash From Financing Activities | 371.8M | 736.7M | 583.0M | 130.3M | 185.7M | 252.4M | |
| End Period Cash Flow | 164.6M | 125.5M | 535.5M | 240.4M | 276.4M | 212.7M | |
| Change To Netincome | 15.1M | 19.9M | 45.7M | 171.8M | 197.6M | 207.4M | |
| Change To Liabilities | 4.2M | 18.1M | 17.8M | 11.3M | 10.2M | 10.7M | |
| Investments | (210.9M) | (535.0M) | 160.3M | (107.4M) | 125.6M | 131.8M | |
| Begin Period Cash Flow | 57.2M | 164.6M | 125.5M | 535.5M | 615.8M | 646.6M | |
| Change To Inventory | 1.7M | 4.9M | 7.8M | (19.5M) | (17.6M) | (16.7M) | |
| Change Receivables | 2.9M | 2.5M | 99K | (1.7M) | (2.0M) | (1.9M) | |
| Cash And Cash Equivalents Changes | (1.6M) | 107.4M | (39.1M) | 410.0M | 471.5M | 495.0M | |
| Cash Flows Other Operating | (27.8M) | 37.0M | (43.7M) | (52.1M) | (46.9M) | (44.5M) | |
| Other Cashflows From Investing Activities | (210.9M) | (538.0M) | 44.8M | (6.6M) | (6.0M) | (6.3M) | |
| Issuance Of Capital Stock | 358.6M | 693.6M | 565.8M | 519.8M | 176.9M | 168.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.25) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets | Return On Equity |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.